New chikungunya vaccine enters first human safety trial

NCT ID NCT07394426

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Gylden Pharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety and side effects, with a final check one year after the last dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PepGNP-ChikV vaccine
What this could lead to: If successful, this could lead to a new type of vaccine that trains the immune system to fight chikungunya virus.
What could go wrong: This is a very early Phase 1 trial with only 40 people, so it is primarily checking safety, not yet proving the vaccine works. Many early-stage vaccines do not advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA CHIKUNGUNYA FEVER CHIKUNGUNYA VIRUS CHIKUNGUNYA VIRUS INFECTION CHIKUNGUNYA VIRUS INFECTIONS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.